Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM.
Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC50s of 66-410 nM.
Tirabrutinib (ONO-4059) is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM.
Tirabrutinib (ONO-4059) is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM.
Tirabrutinib (ONO-4059) is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM.
Tiragolumab is an immune checkpoint inhibitor that binds to T-cell immunoglobulin and the structural domain of ITIM (TIGIT), targets TIGIT and has an intact Fc region. Tiragolumab is indicated for use in studies related to solid tumors.
Tirapazamine (TPZ,SR-4233, WIN 59075) is the first hypoxia-activated prodrug. Tirapazamine kills hypoxic cells by inducing chromosome aberrations and DNA double-strand breaks. Tirapazamine induced cell cycle arrest and apoptosis, and down-regulated HIF-1α, CA-IX and VEGF expression.